Table 1.
Characteristics of 2020 French COVID-19 patients by chronic liver disease.
| Characteristic | Overall, N = 259,1101 |
Chronic liver disease |
p value2 | |
|---|---|---|---|---|
| No, n = 243,634 (94%)1 | Yes, n = 15,476 (6.0%)1 | |||
| Sex | <0.001 | |||
| Male | 135,173 (52%) | 125,659 (52%) | 9,514 (61%) | |
| Female | 123,936 (48%) | 117,974 (48%) | 5,962 (39%) | |
| Age | 70 (54, 83) | 70 (54, 83) | 69 (58, 79) | <0.001 |
| Age category, years | <0.001 | |||
| [18,30) | 12,499 (4.8%) | 12,122 (5.0%) | 377 (2.4%) | |
| [30,40) | 16,222 (6.3%) | 15,582 (6.4%) | 640 (4.1%) | |
| [40,50) | 21,245 (8.2%) | 20,104 (8.3%) | 1,141 (7.4%) | |
| [50,60) | 33,054 (13%) | 30,824 (13%) | 2,230 (14%) | |
| [60,70) | 42,088 (16%) | 38,613 (16%) | 3,475 (22%) | |
| [70,80) | 49,658 (19%) | 45,855 (19%) | 3,803 (25%) | |
| [80,90) | 57,512 (22%) | 54,544 (22%) | 2,968 (19%) | |
| [90,Inf) | 26,832 (10%) | 25,990 (11%) | 842 (5.4%) | |
| Alcohol use disorders | 10,006 (3.9%) | 6,383 (2.6%) | 3,623 (23%) | <0.001 |
| Current or past tobacco use | 15,049 (5.8%) | 12,817 (5.3%) | 2,232 (14%) | <0.001 |
| Obesity | 43,124 (17%) | 39,145 (16%) | 3,979 (26%) | <0.001 |
| Essential (primary) hypertension | 113,407 (44%) | 104,564 (43%) | 8,843 (57%) | <0.001 |
| Diabetes mellitus | 61,664 (24%) | 55,753 (23%) | 5,911 (38%) | <0.001 |
| Modified Charlson comorbidity index | <0.001 | |||
| [0,2) | 170,308 (66%) | 164,165 (67%) | 6,143 (40%) | |
| [2,4) | 57,876 (22%) | 52,764 (22%) | 5,112 (33%) | |
| [4,6) | 20,893 (8.1%) | 18,423 (7.6%) | 2,470 (16%) | |
| [6,8) | 7,651 (3.0%) | 6,404 (2.6%) | 1,247 (8.1%) | |
| [8,Inf) | 2,382 (0.9%) | 1,878 (0.8%) | 504 (3.3%) | |
| Acute respiratory distress syndrome | 67,006 (26%) | 63,041 (26%) | 3,965 (26%) | 0.5 |
| Mechanical ventilation | 18,049 (7.0%) | 16,449 (6.8%) | 1,600 (10%) | <0.001 |
| Acute kidney injury | 12,461 (4.8%) | 11,208 (4.6%) | 1,253 (8.1%) | <0.001 |
| Renal replacement therapy | 2,892 (1.1%) | 2,441 (1.0%) | 451 (2.9%) | <0.001 |
| Pulmonary embolism | 8,179 (3.2%) | 7,647 (3.1%) | 532 (3.4%) | 0.039 |
| Acute liver failure | 1,222 (0.5%) | 552 (0.2%) | 670 (4.3%) | <0.001 |
| Portal vein thrombosis | 148 (<0.1%) | 53 (<0.1%) | 95 (0.6%) | <0.001 |
| Liver disease progression | 17 (<0.1%) | 0 (0%) | 17 (0.1%) | <0.001 |
| Day-30 post-COVID mortality | 38,203 (15%) | 35,262 (14%) | 2,941 (19%) | <0.001 |
Data are for patients who were discharged after COVID-19 between February 1 and December 31, 2020 in France. The 2011-2020 French National Patient Registry was used to indentiy underlying conditions before COVID-19. The Charlson comorbodity index predicts 10-year survival in patients with multiple comorbidities, and ranges from 0 to 30, without entering age and liver disease, with higher scores indicating higher frailty.
1
n (%); Median (IQR).
2
Pearson's Chi-squared test; Wilcoxon rank sum test; Fisher's exact test.